Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2/Neu GP2 vaccine - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology

Next Previous
Drug Profile

HER2/Neu GP2 vaccine - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology

Alternative Names: GLSI-100; GP2 peptide + GM-CSF vaccine; GP2 peptide - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology; HER2/Neu Peptide GP2; HER2/neu peptide vaccine

Latest Information Update: 14 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Uniformed Services University of the Health Sciences
  • Developer Greenwich LifeSciences Inc; NuGenerex Immuno-Oncology
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HER2 positive breast cancer

Most Recent Events

  • 09 Oct 2025 Greenwich LifeSciences announces the addition of Austria to phase III FLAMINGO-01 clinical trial for HER2-positive breast cancer
  • 09 Oct 2025 Greenwich LifeSciences plans to activate site for the phase III FLAMINGO-01 trial in Austria in 2025
  • 02 Oct 2025 Phase-III clinical trials in HER2-positive-breast-cancer (Second-line therapy or greater) in Belgium (Intradermal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top